FDA-Approved Peptides: Selected Drugs and Approval Checks (2026)
Peptide medicines extend well beyond weight management. This selected list explains three categories that often get blurred together: approved drug products, compounded preparations and research materials. Approval status is one part of the picture; clinical evidence, formulation quality and suitability for a particular patient are separate questions. The July 2026 compounding hearing also belongs on a different regulatory track from drug approval.
Approved, compounded, research: three different things
Start with the actual product, not just the molecule’s name. These categories have different evidence and quality frameworks.
FDA-approved drug. Approval covers a specified product and labeling, including its indication and manufacturing controls. Approved generics and biosimilars follow their applicable approval pathways; not every product repeats the original trials.
Compounded. Compounding can meet patient needs, but the resulting medicine is not FDA-approved. Traditional 503A compounding and registered 503B outsourcing facilities have different conditions and oversight; 503B facilities are subject to current good manufacturing practice requirements. FDA explains these distinctions. See compounded semaglutide and compounding pharmacy peptides.
Research-grade. Sold for laboratory research rather than as an approved patient medicine. A research label or seller’s purity certificate does not establish clinical suitability, and that label does not remove applicable legal obligations. See research peptides and are peptides legal.
FDA-approved GLP-1 and metabolic peptides
The GLP-1 class is where FDA-approved peptides became household names. These are all peptide drugs with approved labels:
- Semaglutide — Ozempic and Rybelsus (type 2 diabetes), Wegovy (weight management). See semaglutide vs Ozempic.
- Tirzepatide — Mounjaro (type 2 diabetes), Zepbound (weight management). A dual GIP/GLP-1 agonist. See tirzepatide vs semaglutide.
- Liraglutide — Victoza (diabetes), Saxenda (weight). See liraglutide for weight loss.
- Dulaglutide — Trulicity (diabetes).
- Exenatide — Byetta and Bydureon (diabetes), the first GLP-1 class drug.
Retatrutide, a triple agonist, is still investigational and not approved. See retatrutide FDA approval and the broader GLP-1 guide for what is coming next.
The broader list of FDA-approved peptide drugs
Peptide drugs reach well beyond metabolism. A representative sample by area, not every approved peptide, brand, formulation or indication. Consult the exact current label for patient eligibility and limitations:
| Peptide | Brand | Selected labeled uses |
|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Type 2 diabetes, weight management |
| Tirzepatide | Mounjaro, Zepbound | Type 2 diabetes, weight management |
| Tesamorelin | Egrifta | HIV-associated lipodystrophy |
| Setmelanotide | Imcivree | Certain genetic obesity disorders |
| Bremelanotide | Vyleesi | Hypoactive sexual desire disorder |
| Teriparatide | Forteo | Osteoporosis |
| Abaloparatide | Tymlos | Osteoporosis |
| Linaclotide | Linzess | IBS with constipation, chronic constipation |
| Plecanatide | Trulance | Chronic constipation, IBS-C |
| Octreotide | Sandostatin | Acromegaly, certain tumors |
| Lanreotide | Somatuline Depot | Acromegaly, neuroendocrine tumors |
| Icatibant | Firazyr | Hereditary angioedema attacks |
| Enfuvirtide | Fuzeon | HIV-1 infection |
Insulin and glucagon are peptide hormones with a long approval history of their own. Use the Drugs@FDA application searchto verify a specific medicine rather than infer approval from its marketing category.
Growth-hormone peptides: distinguish products and historical approvals
This category causes the most confusion because the popular names are not approved drugs. Tesamorelin (Egrifta), a growth-hormone-releasing hormone analog, has an approved indication to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight loss. The Egrifta WR labeldescribes an approved powder requiring reconstitution; powder format does not determine approval. See tesamorelin benefits.
Sermorelin was approved as Geref. The 2013 FDA determinationdocuments the discontinued products and 2009 application withdrawals, which were not for safety or effectiveness reasons. It does not establish a manufacturing cause. A compounded version does not inherit historical approval. Ipamorelin, CJC-1295, and hexarelin are not approved products in this list; being offered by a seller is not proof of a lawful compounding pathway. See sermorelin dosage, CJC-1295 and ipamorelin, and growth hormone peptides.
The approved-drug vs research-peptide split
A single molecule can be both an approved drug and a gray-market peptide, depending on the product. Bremelanotide is FDA-approved as Vyleesi, but the same core compound sold as PT-141 for general libido use is not the approved product and is not FDA-reviewed for that use. The lesson: approval attaches to a specific finished product and indication, not to the peptide sequence in the abstract. The FDA-approved Vyleesi label specifies acquired, generalized HSDD in premenopausal women meeting its criteria, not general sexual enhancement.
Popular peptides that are NOT FDA-approved
The following commonly discussed research or wellness peptides should not be confused with approved finished drug products:
- BPC-157 and TB-500 — healing and soft-tissue repair claims; not approved.
- GHK-Cu — skin and hair; not approved as a drug.
- MOTS-c, epitalon — metabolism and longevity; not approved.
- Semax, selank — cognition and anxiety; not approved in the US.
- KPV, thymosin alpha-1 — inflammation and immune; not FDA-approved (thymosin alpha-1 is approved abroad as Zadaxin).
For the full picture of what is legal to buy and how enforcement is shifting, see the FDA peptide ban overview and the “14 peptides legal again” discussion. These linked topics do not establish current legal permission.
Where the July 2026 PCAC hearing fits
FDA’s official July 23–24 meeting pagelists BPC-157, KPV, thymosin beta-4 fragment (often called TB-500), MOTS-c, emideltide (DSIP), Semax and epitalon for consideration under the 503A bulks-list process. Staff assessments, committee recommendations and final FDA actions are different records. Committee advice is nonbinding; this guide has not verified its earlier exact vote counts or predicted 2027 rulemaking timetable. Even a favorable recommendation is not finished-drug approval. The PCAC hearing guide covers the related topic.
The current FDA safety-risk pageseparates active Category 2 entries from withdrawn nominations, including thymosin alpha-1. Withdrawal is not approval or proof that a substance now satisfies compounding requirements. Evidence of benefit and the applicable legal pathway must be evaluated separately.
What "FDA-approved" actually buys you
Verify the exact manufacturer, dosage form, strength, application and labeling in Drugs@FDA. Check whether the product is current or discontinued. An NDC listing is not FDA approval, and a brand name is not enough either. An approved product can require reconstitution; a research vial with the same claimed molecule is not automatically that product. Approval also does not mean risk-free or appropriate for every person. If you are weighing peptide therapy, start with peptide therapy, are peptides safe, and where to buy peptides.
Bottom line
Check the product and its evidence, not just the peptide name or vial format. Approved medicines, legitimate compounded preparations and emerging research answer different questions. A peptide can have promising early data without an approved product; popularity alone does not establish benefit or safety. Likewise, an advisory hearing is not drug approval. Use the current application and label for an approval check, and a separate evidence review for any claimed use.
Frequently Asked Questions About FDA-Approved Peptides
No. BPC-157 has no FDA-approved drug product. FDA’s July 2026 advisory meeting considered its possible use in compounding, a separate question from drug approval. An advisory recommendation or withdrawn nomination does not itself approve a medicine or establish a current compounding pathway.
Yes. Semaglutide and tirzepatide are peptides with FDA-approved products. Their brands, formulations, indications and age limits differ: check the actual product label. Semaglutide acts at GLP-1 receptors; tirzepatide acts at GIP and GLP-1 receptors. Compounded versions are not themselves FDA-approved products.
FDA approval applies to a particular drug product and its approved labeling. Compounding can serve an important patient need, but compounded drugs do not receive FDA premarket approval. Oversight and quality requirements differ between traditional compounding and registered outsourcing facilities. Compounded drugs are not the same as FDA-approved generics.
Bremelanotide is approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women meeting its label criteria, not general sexual enhancement. A research product labeled PT-141 is not thereby the approved Vyleesi product, even if its claimed active compound is bremelanotide.
Sermorelin was approved as Geref. Those products were discontinued, and approval of their applications was withdrawn effective June 18, 2009. FDA’s 2013 determination found that withdrawal from sale was not for safety or effectiveness reasons; it did not establish a manufacturing explanation. A compounded preparation does not inherit Geref’s historical approval.
No FDA-approved thymosin alpha-1 product is identified here. International Zadaxin use or an orphan-drug designation does not establish US marketing approval. FDA’s current safety-risk page places thymosin alpha-1 among substances whose nominations were withdrawn, not its current Category 2 table. That procedural status does not itself authorize compounding.
No. The meeting concerned possible additions to the 503A bulk-substances list, not approval of finished drug products. Committee advice is nonbinding. This guide does not rely on the earlier unsourced vote tallies or a predicted rulemaking date; any final action must be checked separately.
Use Drugs@FDA to match the exact product, manufacturer, dosage form and strength to its application and approved labeling; distinguish current from discontinued products. An NDC number or brand name alone is not proof. Powder requiring reconstitution can be approved: Egrifta WR is one example. Research-use labeling is not a substitute for approval.